Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Elranatamab for treating refractory multiple myeloma after 3 standard therapies have been revised. It is anticipated that the appraisal will begin in early-August 2023 when we will write to you about how you can get involved.